乌鸦传媒

reduced the composite of CV death or heart failure hospitalization in adults with heart failure with reduced ejection fraction, irrespective of diabetes status, in topline results from the EMPEROR-Reduced phase III trial. Full results are slated for presentation at the European Society of Cardiology meeting. (The Pharma Letter)

became the first drug to reduce all-cause mortality in chronic kidney disease patients with positive topline results from the phase III DAPA-CKD trial. It also showed reduction in the primary composite endpoint of worsening renal function or cardiovascular or renal death, AstraZeneca announced.

Clinically stable infection, even without symptoms, researchers reported in the preprint server medRxiv, which is not peer reviewed.

Delaying care for ST-segment elevation MI (STEMI) over fears of coronavirus exposure at the hospital led to in two cases reported in JACC: Case Reports.

SARS-CoV-2 increased , and more so as the pandemic continued. (JACC)

is unlikely to mess with cardiac implanted devices, although getting an iPhone 6 too close could interfere with telemetry. (JACC: Clinical Electrophysiology)

Evolocumab (Repatha) started during a hospitalization for non-STEMI reduced LDL levels significantly, getting most patients to prevention targets by discharge, in the . The researchers called for a trial to prove clinical outcome benefit. (Circulation)

A during bypass surgery in the European Journal of Cardio-Thoracic Surgery was called out on Twitter for "" and "."

An American College of Cardiology group issued for cardiac indications with confirmed or possible SARS-CoV-2 infection.

For suspected coronary artery disease, reclassified risk for a substantial proportion of patients at intermediate risk, suggesting incremental prognostic value. (JAMA Cardiology)

plus left ventricular assist device placement allowed 66% of obese heart failure patients to be waitlisted for heart transplant in a small meta-analysis. (Obesity Surgery)

still spawned about as much secondary research activity as those that succeeded, and both contributed to guidelines. (JAMA Cardiology)

Lack of consistency in effect of achieving certain LDL targets with lipid-lowering drugs should "call into question" LDL as a for CV prevention, according to an analysis in BMJ Evidence-Based Medicine.

Ancestry's for heart disease and other health risks is switching to next-generation sequencing but still isn't diagnostic or FDA approved. (FierceHealthcare)

Comment